# Cybin jumps 19% premarket after announcing phase 2 interim data for CYB003 in major depressive disorder meeting primary efficacy endpoint
**FDA Update**

**2023-10-31 12:20**

**https://www.ainvest.com/news/cybin-jumps-19-premarket-after-announcing-phase-2-interim-data-for-cyb003-in-major-depressive-disorder-meeting-primary-efficacy-endpoint-23101000762d42f6443f5247/**

Cybin jumps 19% premarket after announcing phase 2 interim data for CYB003 in major depressive disorder meeting primary efficacy endpoint